The findings pertaining to the role of HDAC3 in breast cancers differing in ERα status provide worthwhile information on the clinical relevance of the association among these proteins and the development of new therapeutic and prevention strategies against ERα-positive breast cancer. This evidence concerns the gene HDAC3 and breast carcinoma.